MacroGenics Q2 2025 net loss $36.3M; new CEO Eric Risser outlines strategic priorities

MACROGENICS INC

2025-Q2 EPS reported -$1.23 vs consensus -$0.62 ▼ miss (-98.3%)

Cash, equivalents and marketables $176.5M as of June 30, 2025; cash runway through first half 2027.
Total revenue $22.2M ($15.4M contract manufacturing, $6.9M collaboration vs. $10.8M year ago).
Net loss improved to $36.3M ($0.57/share) from $55.7M ($0.89/share) in Q2 2024.
Eric Risser named President and CEO, succeeding Scott Koenig who stepped down after 24 years.
Received $70M upfront from Sagard Healthcare for ZYNYZ royalty purchase agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.